Core Viewpoint - The company has signed a partnership asset transfer agreement with Shanghai Hongyuan Investment Group, transferring 30% of its stake in Jiaxing Yuanfan Venture Capital Partnership, which is expected to enhance financial efficiency and focus on core business operations [1] Group 1 - The company will transfer its 30% stake in Jiaxing Yuanfan, with a subscribed capital of 30 million yuan and a paid-in capital of 12 million yuan, for a transfer price of 12 million yuan [1] - After the completion of the transfer, the company will no longer hold any stake in Jiaxing Yuanfan [1] - This transaction is beneficial for the company to recover funds and improve asset operation efficiency, positively impacting its financial status [1]

一、 交易概述 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）于 2023 年 5 月 26 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于参与投资 设立新产业投资基金的公告》（公告编号：2023-046），公司与上海元藩投资有 限公司、上海鸿元投资集团有限公司、盛雷鸣、潘苏航共同签署了《嘉兴远帆 创业投资合伙企业（有限合伙）之有限合伙协议》（以下简称"合伙协议"），拟 共同设立嘉兴远帆创业投资合伙企业（有限合伙）（以下简称"合伙企业"或 "嘉兴远帆"）。合伙企业本期计划募集资金人民币 10,000 万元，其中公司作为 有限合伙人拟以自有资金出资认缴人民币 3,000 万元，占合伙企业认缴出资额 的 30%。2023 年 10 月 24 日，公司在巨潮资讯网（www.cninfo.com.cn）披露了 《关于参与投资设立新产业投资基金的进展公告》（公告编号：2023-076）。 近日，公司基于战略布局和未来发展规划，经与嘉兴远帆各方充分沟通并 友好协商，公司与上海鸿元投资集团有限公司签署了《合伙企业财产份额转让 协议》（以下简称"本协议"），将公司持有嘉兴远帆 30%的财产 ...

Market Overview - On September 17, the medical device sector experienced a decline of 0.22%, with Toujing Life leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Notable gainers in the medical device sector included: - Hualan Biological (301093) with a closing price of 39.01, up 5.20% and a trading volume of 85,900 shares, totaling a transaction value of 330 million yuan [1] - Xinhua Medical (600587) closed at 17.16, up 5.08% with a trading volume of 451,500 shares, totaling 767 million yuan [1] - Haooubo (688656) closed at 168.52, up 5.00% with a trading volume of 16,600 shares, totaling 272 million yuan [1] - Conversely, the following companies saw significant declines: - Toujing Life (300642) closed at 24.55, down 7.53% with a trading volume of 168,900 shares, totaling 426 million yuan [2] - Jimin Health (603222) closed at 13.22, down 4.06% with a trading volume of 748,900 shares, totaling 995 million yuan [2] - Meihua Medical (301363) closed at 27.31, down 2.95% with a trading volume of 153,300 shares, totaling 422 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 894 million yuan from institutional investors, while retail investors contributed a net inflow of 818 million yuan [2] - Notable capital flows included: - Haooubo (688656) with a net inflow of 39.06 million yuan from institutional investors, but a net outflow of 23.69 million yuan from speculative funds [3] - Xinhua Medical (600587) had a net inflow of 38.89 million yuan from institutional investors, with a net outflow of 64.90 million yuan from speculative funds [3] - Hualan Biological (301093) recorded a net inflow of 24.68 million yuan from institutional investors, while retail investors saw a net outflow of 25.99 million yuan [3]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a significant stock price increase of 5.18%, reaching 39.00 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 4.34%, resulting in a total market capitalization of 6.404 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main business revenue composition being 49.07% from film-coated rubber stoppers, 48.50% from conventional rubber stoppers, and 2.43% from other products [1] Group 2 - From the perspective of fund holdings, Dachen Fund has a significant position in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value, making it the eighth largest holding [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 25.08% and a one-year return of 45.68%, ranking 3502 out of 8172 and 3660 out of 7980 respectively in its category [2] - The fund manager, Zou Jian, has been in position for 4 years and 236 days, with the fund's total asset size being 1.086 billion yuan, and the best and worst returns during his tenure being 13.52% and -21.29% respectively [2]

证券代码：301093 证券简称：华兰股份 公告编号：2025-093 江苏华兰药用新材料股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、 本次股东会未出现否决议案的情形。 一、 会议召开和出席情况 （一） 会议召开时间 通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 9 月 15 日 （星期一）9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 15 日（星期一）9:15-15:00。 （二） 现场会议召开地点：江苏省江阴市申港镇镇澄路 1488 号江苏华兰 药用新材料股份有限公司会议室。 2、 本次股东会未涉及变更以往股东会已通过的决议。 3、 本次股东会审议各项议案均对中小股东的表决单独计票。 1、 现场会议召开时间：2025 年 9 月 15 日（星期一）下午 14:30 2、 网络投票时间：2025 年 9 月 15 日（星期一） （三） 会议召开方式：采取现场投票与网络投票相结 ...

北京植德（上海）律师事务所 关于江苏华兰药用新材料股份有限公司 2025 年第四次临时股东会的 法律意见书 植德沪(会)字[2025]0042 号 二〇二五年九月 上海市徐汇区虹桥路 183 号徐家汇中心三期 A 座办公楼 27 层 邮编：200030 27th Floor Tower A, THREE itc, No.183 Hongqiao Road, Xuhui District, Shanghai 200030 P.R.C 电话(Tel)：021-52533500 传真(Fax)：021-52533599 www.meritsandtree.com 北京植德（上海）律师事务所 关于江苏华兰药用新材料股份有限公司 2025年第四次临时股东会的 法律意见书 植德沪(会)字[2025]0042号 致：江苏华兰药用新材料股份有限公司 北京植德（上海）律师事务所（以下简称"本所"）接受江苏华兰药用新材 料股份有限公司（以下简称"公司"或"华兰股份"）的委托，指派律师出席并 见证公司2025年第四次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共 ...

Group 1 - The core point of the article is that Hualan Co., Ltd. has established a wholly-owned subsidiary in Nanjing with an investment of 5 million RMB [1] - The newly established subsidiary will be included in the company's consolidated financial statements [1] - The subsidiary has completed the business registration process and obtained a business license from the Nanjing Qinhuai District Administrative Service Management Office [1]

Core Viewpoint - The company, Hualan Co., Ltd. (301093.SZ), has established a wholly-owned subsidiary in Nanjing with an investment of 5 million RMB to support its strategic layout and industrial development [1] Group 1: Investment and Subsidiary Establishment - Hualan Co., Ltd. has invested 5 million RMB to set up a wholly-owned subsidiary, Hualan Nanjing Sun Company, in Nanjing [1] - The newly established subsidiary has completed the business registration process and obtained a business license from the Nanjing Qinhuai District Administrative Service Management Office [1] - This investment is aimed at developing new business growth points, expanding influence, and promoting the healthy development of the company [1]

Core Viewpoint - Hualan Co., Ltd. has established a wholly-owned subsidiary in Nanjing with an investment of 5 million RMB to support its strategic layout and industrial development [1] Group 1: Investment and Subsidiary Establishment - The company’s subsidiary, Tibet Hualan Tibetan Medicine Technology Co., Ltd., has invested 5 million RMB to set up a wholly-owned subsidiary in Nanjing [1] - The newly established subsidiary will be included in the company’s consolidated financial statements [1] - The subsidiary has completed the business registration process and obtained a business license from the Nanjing Qinhuai District Administrative Service Management Office [1] Group 2: Strategic Importance - This external investment is aimed at meeting the company’s strategic layout and industrial development needs [1] - The establishment of the Nanjing subsidiary is expected to help develop new business growth points, expand influence, and promote healthy development of the company [1]

江苏华兰药用新材料股份有限公司 关于设立南京孙公司并完成工商登记的公告 证券代码：301093 证券简称：华兰股份 公告编号：2025-092 | 一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技 | 术推广；健康咨询服务（不含诊疗服务）；医学研究和试验发展；医学 | | | --- | --- | --- | | 研究和试验发展（除人体干细胞、基因诊断与治疗技术开发和应用）； | 化妆品零售；日用百货销售；个人卫生用品销售；卫生用品和一次性使 | | | 用医疗用品销售；美发饰品销售；日用杂品销售；养生保健服务（非医 | 疗）；保健食品（预包装）销售（除依法须经批准的项目外，凭营业执 | | | 照依法自主开展经营活动） | 西藏华兰藏医药科技有限公司持有其 | 100%股份，公司间接持有其 | | 股权结构 | 61.40%股份。 | | 三、 对外投资的目的和对公司的影响 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 对外投资概述 为满足江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股 份"）战略布局和产业发展的需要，公司 ...